These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 27221849)

  • 21. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
    McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
    Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
    Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
    Wu TI; Hsu KH; Huang HJ; Hsueh S; Chou HH; Tsai CS; Ho KC; Chao A; Chang TC; Lai CH
    Eur J Gynaecol Oncol; 2008; 29(5):483-8. PubMed ID: 19051818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
    Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
    Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
    Otsuki A; Watanabe Y; Nomura H; Futagami M; Yokoyama Y; Shibata K; Kamoi S; Arakawa A; Nishiyama H; Katsuta T; Kudaka W; Shimada M; Sato N; Kotera K; Katabuchi H; Yaegashi N
    Int J Gynecol Cancer; 2015 Jan; 25(1):92-7. PubMed ID: 25347097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
    Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
    Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
    Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
    Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy.
    Pacaut C; Bourmaud A; Rivoirard R; Moriceau G; Guy JB; Collard O; Bosacki C; Jacquin JP; Levy A; Chauleur C; Magné N; Merrouche Y
    Am J Clin Oncol; 2015 Jun; 38(3):272-7. PubMed ID: 23751320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.
    Makker V; Kravetz SJ; Gallagher J; Orodel OP; Zhou Q; Iasonos A; DeLair D; Aghajanian C; Hensley ML
    Int J Gynecol Cancer; 2013 Nov; 23(9):1635-41. PubMed ID: 24172099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
    Friedman CF; Hensley ML
    Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
    Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
    J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
    Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
    Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of 80 cases with uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma in China, 1988-2007.
    Gao Y; Meng H; Zhang Y; Jiao T; Hui N
    Int J Clin Exp Pathol; 2014; 7(4):1616-24. PubMed ID: 24817958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Adjuvant Chemotherapy, Radiation Therapy, or Combined Modality Therapy and the Impact on Survival for Uterine Carcinosarcoma Limited to the Pelvis.
    Wong AT; Lee YC; Schwartz D; Lee A; Shao M; Han P; Choi K; Schreiber D
    Int J Gynecol Cancer; 2017 Jul; 27(6):1171-1177. PubMed ID: 28574930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
    Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
    Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.